Directory
Portfolio companies.
34,000+ PE-backed.
Active investments and exits across European private equity portfolios.
Filter by sector, geography, status. Find the right deal comp in seconds.
Active deals
5
currently held
Exits tracked
5
hand-checked
Sectors covered
1
across the portfolio
Countries covered
1
from every market
Latest activity
Caledonia InvestmentscapitalCapital Event · capital-cancellation-shares · Capital structure change1 week agoCapital Event · capital-cancellation-shares · Capital structure change
capitalCaledonia InvestmentscapitalCapital Event · capital-cancellation-shares · Capital structure change1 week agoCapital Event · capital-cancellation-shares · Capital structure change
capitalCaledonia InvestmentscapitalCapital Event · capital-cancellation-shares · Capital structure change1 week agoCapital Event · capital-cancellation-shares · Capital structure change
capital
Elaia PartnersadminCEO change · Departure of CEO Gire, Philippe · CEO departure · leadership transition underway2 weeks agoCEO change · Departure of CEO Gire, Philippe · CEO departure · leadership transition underway
adminLauxera Capital PartnersadminBoard change · Management board member change: et Directeur général délégué Fracchia, Edoardo · Change in the management board1 month agoBoard change · Management board member change: et Directeur général délégué Fracchia, Edoardo · Change in the management board
admin9 companies matching
| Company | Sector | Geo | Investor | Entry | Hold | Status | Buyer | MOIC | |
|---|---|---|---|---|---|---|---|---|---|
Biocrates MIG Fonds 16 | MIG Capital | 2019 | 6yr | Exited 2025 | Bruker Corporation | – | |||
Hookipa Pharma2 periods Sofinnova Capital IX | Sofinnova Partners | 2013 | 6yr | Exited 2025 | Gilead Sciences | – | |||
Themis Bioscience Wellington Partners Life Sciences | Wellington Partners | 2015 | 5yr | Exited 2020 | Merck & Co. (MSD) | – | |||
ViraTherapeutics Boehringer Ingelheim Venture Fund | Boehringer Ingelheim Venture Fund | 2013 | 5yr | Exited 2018 | Boehringer Ingelheim | – | |||
AFFiRiS MIG Fonds 5 | MIG Capital | 2006 | 20yr | Active | – | – | |||
cutanos HTGF III | High-Tech Gruenderfonds (HTGF) | 2021 | 5yr | Active | – | – | |||
Graph Therapeutics2 periods SquareOne III | SquareOne | 2024 | 2yr | Active | – | – | |||
Fermify Simon Capital Evergreen | Simon Capital | 2023 | 3yr | Active | – | – | |||
QUANTRO Therapeutics Boehringer Ingelheim Venture Fund | Boehringer Ingelheim Venture Fund | 2020 | 6yr | Active | – | – |
Biocrates
MIG Fonds 16
AustriaSector
Biotech
InvestorMIG Capital
Entry
2019
Hold
6yr
Exit
2025
to Bruker Corporation
Hookipa Pharma
Sofinnova Capital IX
AustriaSector
Biotech
InvestorSofinnova Partners
Entry
2013
Hold
6yr
Owners
2
Exit
2025
to Gilead Sciences
Themis Bioscience
Wellington Partners Life Sciences
AustriaSector
Biotech
InvestorWellington Partners
Entry
2015
Hold
5yr
Exit
2020
to Merck & Co. (MSD)
ViraTherapeutics
Boehringer Ingelheim Venture Fund
AustriaSector
Biotech
InvestorBoehringer Ingelheim Venture Fund
Entry
2013
Hold
5yr
Exit
2018
to Boehringer Ingelheim
AFFiRiS
MIG Fonds 5
AustriaSector
Biotech
InvestorMIG Capital
Entry
2006
Hold
20yr
cutanos
HTGF III
AustriaSector
Biotech
InvestorHigh-Tech Gruenderfonds (HTGF)
Entry
2021
Hold
5yr
Graph Therapeutics
SquareOne III
AustriaSector
Biotech
InvestorSquareOne
Entry
2024
Hold
2yr
Owners
2
Fermify
Simon Capital Evergreen
AustriaSector
Biotech
InvestorSimon Capital
Entry
2023
Hold
3yr
QUANTRO Therapeutics
Boehringer Ingelheim Venture Fund
AustriaSector
Biotech
InvestorBoehringer Ingelheim Venture Fund
Entry
2020
Hold
6yr